SuppreMol GmbH : SuppreMol appoints industry expert Klaus Schollmeier as CEO
SuppreMol GmbH / SuppreMol appoints industry expert Klaus Schollmeier as CEO .
Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.
Munich, Germany, April 02, 2013: SuppreMol GmbH, a privately held
biopharmaceutical company developing novel therapies for the treatment of
autoimmune diseases, today announced the appointment of Dr. Klaus Schollmeier
as Chief Executive Officer (CEO) of the Company with effect April 1st, 2013.
Dr. Schollmeier succeeds Prof. Dr. Peter Buckel, who resigns as CEO having
reached retirement age.
Dr. Schollmeier has more than 25 years of successful international management
experience in the pharmaceutical and biotech industry as well as in investment
banking. Dr. Schollmeier led Santhera Pharmaceuticals AG as CEO since the
company's foundation in 2004 and acts as Chairman of the Board since October
2011. Previously, he was Managing Director Healthcare / Biotechnology at ING
BHF-Bank. Before this, he spent 16 years in the pharmaceutical industry at
BASF, Knoll and Abbott. His scientific responsibilities included head of
oncology/immunology research at BASF's central laboratories in Germany, and
senior director of biotechnology at BASF Bioresearch Corporation in Cambridge,
US. His business functions included General Manager of BASF Pharma Netherlands
and Vice President and General Manager for Western Europe. Mr. Schollmeier
holds a Ph.D. in Biology from the University of Düsseldorf, Germany.
Dr. Thomas Hecht, Chairman of the Advisory Board of SuppreMol GmbH, said: "We
are very pleased to have Dr. Schollmeier joining our Company at a time when
SuppreMol is entering a new and exciting phase. The Company has a very
promising product candidate for the treatment of autoimmune diseases in phase
II clinical development with important clinical and regulatory milestones
ahead. Dr. Schollmeier will bring the necessary experience to the Company to
advance SuppreMol's products towards a BLA (Biologics License Application)."
Dr. Hecht added: "On behalf of the Board I would like to thank Prof. Dr. Peter
Buckel for his long-standing commitment to the success of SuppreMol and his
valuable contributions in building the company over the past years."
"I look forward to leading SuppreMol in the exciting years to come.
SuppreMol's product candidates are based on innovative science and have shown
promising data in early clinical trials," stated Dr. Klaus Schollmeier, the
Chief Executive Officer of SuppreMol GmbH. "I will lead the corporate and
commercial development of SuppreMol in the years to come with the ambition to
successfully advance the key assets, in particular the lead program SM101."
SuppreMol GmbH is a privately held biopharmaceutical company developing novel
therapeutics for the treatment of autoimmune and allergic diseases. The
company is pioneering the development of soluble Fc-gamma receptors (FcgRs),
which are recombinant autologous therapeutic proteins with a specific
immunoregulatory potential. The company's lead product SM101, a recombinant
soluble FcgRIIB is in phase II clinical development for the treatment of
Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE)
and has potential to treat Rheumatoid Arthritis (RA) and other autoimmune
conditions. SuppreMol's pipeline also includes two antibody development
programs utilizing the inhibitory effect of FcgRIIB suitable for alternative
treatment strategies and indications as well as an anti-IL-3 antibody to treat
RA. SuppreMol was founded as a spin-off from the laboratory of Prof. Dr.
Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck
Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has
raised € 40.3 million through private investors. Major shareholders in the
company include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP
Biotech Holding GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max
Planck Society, and Z-Cube.
Dr. Klaus Schollmeier
Chief Executive Officer
Tel: +49 89 30 90 50 680
Press Release PDF
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: SuppreMol GmbH via Thomson Reuters ONE
--- End of Message ---
Am Klopferspitz 19 Martinsried/Munich Germany
Press spacebar to pause and continue. Press esc to stop.